Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 410

1.

Liver Transplantation for Hepatocellular Carcinoma: Management After the Transplant.

Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY; This manuscript is a work-product of the American Society of Transplantation Liver Intestine Community of Practice.

Am J Transplant. 2019 Nov 11. doi: 10.1111/ajt.15697. [Epub ahead of print]

PMID:
31710773
2.

USP22 interacts with PALB2 and promotes chemotherapy resistance via homologous recombination of DNA double strand breaks.

Nardi IK, Stark JM, Larsen A, Salgia R, Raz DJ.

Mol Cancer Res. 2019 Nov 4. pii: molcanres.0053.2019. doi: 10.1158/1541-7786.MCR-19-0053. [Epub ahead of print]

PMID:
31685642
3.

Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS.

Kalvala A, Wallet P, Yang L, Wang C, Li H, Nam A, Nathan A, Mambetsariev I, Poroyko V, Gao H, Chu P, Sattler M, Bild A, Manuel ER, Lee PP, Jolly MK, Kulkarni P, Salgia R.

J Clin Med. 2019 Oct 18;8(10). pii: E1726. doi: 10.3390/jcm8101726.

4.

Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells.

Mirzapoiazova T, Li H, Nathan A, Srivstava S, Nasser MW, Lennon F, Armstrong B, Mambetsariev I, Chu PG, Achuthan S, Batra SK, Kulkarni P, Salgia R.

J Clin Med. 2019 Oct 18;8(10). pii: E1723. doi: 10.3390/jcm8101723.

5.

EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.

Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, Sattler M, Vaidehi N, Mambetsariev I, Kindler HL, Wheeler DL, Salgia R.

Oncogenesis. 2019 Sep 4;8(9):49. doi: 10.1038/s41389-019-0159-6.

6.

Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.

Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK.

J Thorac Oncol. 2019 Oct;14(10):1718-1731. doi: 10.1016/j.jtho.2019.08.012. Epub 2019 Aug 27.

PMID:
31470129
7.

Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.

Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC.

Gastroenterology. 2019 Nov;157(5):1253-1263.e2. doi: 10.1053/j.gastro.2019.07.040. Epub 2019 Jul 30.

PMID:
31374215
8.

Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma.

Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG.

Clin Gastroenterol Hepatol. 2019 Jul 26. pii: S1542-3565(19)30786-4. doi: 10.1016/j.cgh.2019.07.042. [Epub ahead of print]

PMID:
31357028
9.

The Mitochondrion as an Emerging Therapeutic Target in Cancer.

Roth KG, Mambetsariev I, Kulkarni P, Salgia R.

Trends Mol Med. 2019 Jul 18. pii: S1471-4914(19)30171-6. doi: 10.1016/j.molmed.2019.06.009. [Epub ahead of print] Review.

PMID:
31327706
10.

Notch signaling in breast cancer: From pathway analysis to therapy.

Krishna BM, Jana S, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS.

Cancer Lett. 2019 Oct 1;461:123-131. doi: 10.1016/j.canlet.2019.07.012. Epub 2019 Jul 18.

PMID:
31326555
11.

Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes.

DuBrock HM, Salgia RJ, Sussman NL, Bartolome SD, Kadry Z, Mulligan DC, Jenkins S, Lackore K, Channick RN, Kawut SM, Krowka MJ.

Transplant Direct. 2019 May 22;5(6):e456. doi: 10.1097/TXD.0000000000000900. eCollection 2019 Jun.

12.

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.

Mambetsariev I, Mirzapoiazova T, Lennon F, Jolly MK, Li H, Nasser MW, Vora L, Kulkarni P, Batra SK, Salgia R.

J Clin Med. 2019 Jul 16;8(7). pii: E1038. doi: 10.3390/jcm8071038.

13.

Successful Management of Patients with Co-existent Graves' Disease and Autoimmune Hepatitis.

Rana S, Ahmed Z, Salgia R, Bhan A.

Cureus. 2019 May 11;11(5):e4647. doi: 10.7759/cureus.4647.

14.

Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.

Ramírez J, House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, Ratain MJ, Sharma MR.

J Clin Pharmacol. 2019 Dec;59(12):1632-1640. doi: 10.1002/jcph.1476. Epub 2019 Jul 5.

PMID:
31274208
15.

Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.

Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS.

J Thorac Oncol. 2019 Oct;14(10):1704-1717. doi: 10.1016/j.jtho.2019.06.020. Epub 2019 Jun 28.

PMID:
31260832
16.

Targeted Therapies in Non-small-Cell Lung Cancer.

Hill A, Gupta R, Zhao D, Vankina R, Amanam I, Salgia R.

Cancer Treat Res. 2019;178:3-43. doi: 10.1007/978-3-030-16391-4_1.

PMID:
31209840
17.

Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.

Shinde A, Horne ZD, Li R, Glaser S, Massarelli E, Koczywas M, Erhunmwunsee L, Reckamp KL, Weksler B, Salgia R, Beriwal S, Amini A.

Lung Cancer. 2019 Jul;133:136-143. doi: 10.1016/j.lungcan.2019.05.020. Epub 2019 May 19.

PMID:
31200820
18.

Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.

Singhal SS, Horne D, Singhal J, Vonderfecht S, Salgia R, Awasthi S.

Mol Carcinog. 2019 Aug;58(8):1438-1449. doi: 10.1002/mc.23026. Epub 2019 Apr 21.

PMID:
31006917
19.

Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.

Wang C, Kulkarni P, Salgia R.

Mol Ther Oncolytics. 2019 Mar 19;13:1-6. doi: 10.1016/j.omto.2019.02.001. eCollection 2019 Jun 28. Review.

20.

Early mortality of stage IV non-small cell lung cancer in the United States.

Amini A, Verma V, Glaser SM, Shinde A, Sampath S, Stokes WA, Rusthoven CG, Massarelli E, Salgia R, Gaspar LE, Liu AK.

Acta Oncol. 2019 Aug;58(8):1095-1101. doi: 10.1080/0284186X.2019.1599138. Epub 2019 Apr 8.

PMID:
30958075
21.

Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer.

Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL.

Mol Cancer Ther. 2019 Apr;18(4):868. doi: 10.1158/1535-7163.MCT-18-1183. No abstract available.

PMID:
30936412
22.

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.

Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R.

Clin Transl Med. 2019 Mar 18;8(1):9. doi: 10.1186/s40169-019-0225-x. Review.

23.

Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level.

Lin X, Kulkarni P, Bocci F, Schafer NP, Roy S, Tsai MY, He Y, Chen Y, Rajagopalan K, Mooney SM, Zeng Y, Weninger K, Grishaev A, Onuchic JN, Levine H, Wolynes PG, Salgia R, Rangarajan G, Uversky V, Orban J, Jolly MK.

Biomolecules. 2019 Feb 22;9(2). pii: E77. doi: 10.3390/biom9020077.

24.

RLIP: An existential requirement for breast carcinogenesis.

Singhal SS, Salgia R, Singhal S, Horne D, Awasthi S.

Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):281-288. doi: 10.1016/j.bbcan.2019.02.001. Epub 2019 Feb 13. Review.

PMID:
30771458
25.

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.

Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R.

Am J Clin Oncol. 2019 Apr;42(4):337-344. doi: 10.1097/COC.0000000000000508.

PMID:
30741758
26.

RLIP inhibition suppresses breast-to-lung metastasis.

Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS.

Cancer Lett. 2019 Apr 10;447:24-32. doi: 10.1016/j.canlet.2019.01.023. Epub 2019 Jan 23.

PMID:
30684594
27.

Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND.

Gastroenterology. 2019 May;156(6):1683-1692.e1. doi: 10.1053/j.gastro.2019.01.027. Epub 2019 Jan 18.

PMID:
30660729
28.

The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer.

Hewelt B, Li H, Jolly MK, Kulkarni P, Mambetsariev I, Salgia R.

Bioinformatics. 2019 Aug 15;35(16):2738-2748. doi: 10.1093/bioinformatics/bty1021.

29.

Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2018 Dec 1;24(23):6099. doi: 10.1158/1078-0432.CCR-18-3194. No abstract available.

PMID:
30510088
30.

Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.

Wang J, Mirzapoiazova T, Carol Tan YH, Pang KM, Pozhitkov A, Wang Y, Wang Y, Mambetsariev B, Wang E, Nasser MW, Batra SK, Raz D, Reckamp K, Kulkarni P, Zheng Y, Salgia R.

Cancer Biol Ther. 2018;19(11):1023-1032. doi: 10.1080/15384047.2018.1472193. Epub 2018 Oct 12.

31.

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.

Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R.

Clin Transl Med. 2018 Oct 8;7(1):32. doi: 10.1186/s40169-018-0210-9. Review.

32.

Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.

Shinde A, Li R, Kim J, Salgia R, Hurria A, Amini A.

Semin Oncol. 2018 Aug;45(4):210-219. doi: 10.1053/j.seminoncol.2018.06.002. Epub 2018 Jul 1. Review.

PMID:
30286944
33.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

34.

2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.

Nagaprashantha LD, Singhal J, Chikara S, Gugiu G, Horne D, Awasthi S, Salgia R, Singhal SS.

J Proteomics. 2019 Feb 10;192:233-245. doi: 10.1016/j.jprot.2018.09.005. Epub 2018 Sep 21.

PMID:
30248461
35.

Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone.

Singhal J, Singhal P, Horne D, Salgia R, Awasthi S, Singhal SS.

Cancer Lett. 2018 Dec 1;438:144-153. doi: 10.1016/j.canlet.2018.09.015. Epub 2018 Sep 15.

PMID:
30223070
36.

2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.

Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS.

Mol Carcinog. 2018 Dec;57(12):1751-1762. doi: 10.1002/mc.22894. Epub 2018 Sep 19.

PMID:
30136444
37.

Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.

Hill A, Gong J, Wilczynski S, Mirza R, Erhunmwunsee L, Salgia R.

J Oncol Pract. 2018 Sep;14(9):569-571. doi: 10.1200/JOP.18.00127. Epub 2018 Jul 25. No abstract available.

PMID:
30044685
38.

Heuristic value-based framework for lung cancer decision-making.

Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R.

Oncotarget. 2018 Jul 6;9(52):29877-29891. doi: 10.18632/oncotarget.25643. eCollection 2018 Jul 6.

39.

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR.

Cancer Chemother Pharmacol. 2018 Aug;82(2):309-317. doi: 10.1007/s00280-018-3619-3. Epub 2018 Jun 9.

40.

Graft-versus-host disease of the central nervous system after liver transplantation: A rare complication.

Pahari H, Nagai S, Skorupski S, Salgia R.

Am J Transplant. 2018 Oct;18(10):2591-2594. doi: 10.1111/ajt.14981. Epub 2018 Jul 20.

41.

Chances of Renal Recovery or Liver Transplantation After Hospitalization for Alcoholic Liver Disease Requiring Dialysis.

Lenhart A, Hussain S, Salgia R.

Dig Dis Sci. 2018 Oct;63(10):2800-2809. doi: 10.1007/s10620-018-5170-9. Epub 2018 Jun 22.

PMID:
29934721
42.

Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.

Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P.

J Clin Med. 2018 Jun 17;7(6). pii: E156. doi: 10.3390/jcm7060156. Review.

43.

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.

Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V, Wang Y, Sattler M.

Oncotarget. 2018 May 25;9(40):26226-26242. doi: 10.18632/oncotarget.25360. eCollection 2018 May 25. Review.

44.

Managing Patients With Relapsed Small-Cell Lung Cancer.

Gong J, Salgia R.

J Oncol Pract. 2018 Jun;14(6):359-366. doi: 10.1200/JOP.18.00204. Review.

45.

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients.

Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R.

Oncotarget. 2018 Apr 13;9(28):19793-19806. doi: 10.18632/oncotarget.24857. eCollection 2018 Apr 13.

46.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
47.

2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer.

Nagaprashantha LD, Singhal J, Li H, Warden C, Liu X, Horne D, Awasthi S, Salgia R, Singhal SS.

Oncotarget. 2018 Apr 6;9(26):18053-18068. doi: 10.18632/oncotarget.24720. eCollection 2018 Apr 6.

48.

Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.

Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R.

Eur Urol. 2018 Jul;74(1):124-128. doi: 10.1016/j.eururo.2018.03.032. No abstract available.

PMID:
29685646
49.

Value-based genomics.

Gong J, Pan K, Fakih M, Pal S, Salgia R.

Oncotarget. 2018 Jan 30;9(21):15792-15815. doi: 10.18632/oncotarget.24353. eCollection 2018 Mar 20. Review.

50.

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.

Mambetsariev I, Vora L, Yu KW, Salgia R.

BMC Cancer. 2018 Mar 21;18(1):314. doi: 10.1186/s12885-018-4222-z.

Supplemental Content

Loading ...
Support Center